Infant with Rare CPS1 Deficiency Goes Home After Pioneering Personalized CRISPR Therapy

CRISPR base editing delivered via lipid nanoparticles restored CPS1 enzyme activity; ammonia levels declined rapidly following FDA’s expedited review.